Drugs / Pegylated Recombinant Human Arginase I
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00988195 | May 2008 → Aug 2009 | hepatocellular carcinoma | Bio-Cancer Treatment International Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01092091 | Mar 2010 → Feb 2012 | hepatocellular carcinoma | Bio-Cancer Treatment International Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Recombinant Human Arginase I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01092091 ↗ |
| Known as | rhArgIpeg5000 | “To establish a safe dose level for weekly intravenous administration of PEG- BCT-100 (rhArgIpeg5000) based on clinical and laboratory safety assessments following a range of...” NCT00988195 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human arginase (PEG-BCT-100)” NCT00988195 ↗ |
| Route | Intravenous | “weekly intravenous administration” NCT00988195 ↗ |